Cargando…

Reference Interval for the Axis-Shield Clinical Chemistry Heparin-Binding Protein Assay

The newly developed Axis-Shield clinical chemistry heparin-binding protein (HBP) assay (Axis-Shield Diagnostics Ltd., Dundee, Scotland) can be applied to fully automated platforms. We aimed to establish a reference interval (RI) of HBP using the Axis-Shield HBP assay, and to evaluate the analytical...

Descripción completa

Detalles Bibliográficos
Autores principales: Yoon, Sumi, Hur, Mina, Kim, Hanah, Moon, Hee-Won, Yun, Yeo-Min
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9406967/
https://www.ncbi.nlm.nih.gov/pubmed/36010280
http://dx.doi.org/10.3390/diagnostics12081930
_version_ 1784774250790387712
author Yoon, Sumi
Hur, Mina
Kim, Hanah
Moon, Hee-Won
Yun, Yeo-Min
author_facet Yoon, Sumi
Hur, Mina
Kim, Hanah
Moon, Hee-Won
Yun, Yeo-Min
author_sort Yoon, Sumi
collection PubMed
description The newly developed Axis-Shield clinical chemistry heparin-binding protein (HBP) assay (Axis-Shield Diagnostics Ltd., Dundee, Scotland) can be applied to fully automated platforms. We aimed to establish a reference interval (RI) of HBP using the Axis-Shield HBP assay, and to evaluate the analytical performance of this assay. An RI was established in 212 sodium citrated plasma samples using the non-parametric method (2.5th and 97.5th percentiles). Precision, linearity, and carry-over were evaluated according to the Clinical and Laboratory Standards Institute guidelines. The RI of HBP was between 5.3 ng/mL and 171.0 ng/mL, which could be applied regardless of gender and age. Percentage coefficients of variations (%CVs) of repeatability and within-laboratory precision were 4.9% and 6.3%, respectively, for low-concentration control and 1.6% and 3.0%, respectively, for high-concentration control. The linearity was excellent (coefficient of determination (R(2)) = 0.99), and the carry-over rate was negligible (0.05%). This is the first study to establish an RI of HBP using the newly developed and fully automated Axis-Shield HBP assay. The Axis-Shield HBP assay showed an acceptable level of analytical performance and could be used to measure HBP concentrations effectively in routine clinical practice. Further studies are awaited to evaluate the clinical utility of HBP using this automated assay.
format Online
Article
Text
id pubmed-9406967
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-94069672022-08-26 Reference Interval for the Axis-Shield Clinical Chemistry Heparin-Binding Protein Assay Yoon, Sumi Hur, Mina Kim, Hanah Moon, Hee-Won Yun, Yeo-Min Diagnostics (Basel) Article The newly developed Axis-Shield clinical chemistry heparin-binding protein (HBP) assay (Axis-Shield Diagnostics Ltd., Dundee, Scotland) can be applied to fully automated platforms. We aimed to establish a reference interval (RI) of HBP using the Axis-Shield HBP assay, and to evaluate the analytical performance of this assay. An RI was established in 212 sodium citrated plasma samples using the non-parametric method (2.5th and 97.5th percentiles). Precision, linearity, and carry-over were evaluated according to the Clinical and Laboratory Standards Institute guidelines. The RI of HBP was between 5.3 ng/mL and 171.0 ng/mL, which could be applied regardless of gender and age. Percentage coefficients of variations (%CVs) of repeatability and within-laboratory precision were 4.9% and 6.3%, respectively, for low-concentration control and 1.6% and 3.0%, respectively, for high-concentration control. The linearity was excellent (coefficient of determination (R(2)) = 0.99), and the carry-over rate was negligible (0.05%). This is the first study to establish an RI of HBP using the newly developed and fully automated Axis-Shield HBP assay. The Axis-Shield HBP assay showed an acceptable level of analytical performance and could be used to measure HBP concentrations effectively in routine clinical practice. Further studies are awaited to evaluate the clinical utility of HBP using this automated assay. MDPI 2022-08-10 /pmc/articles/PMC9406967/ /pubmed/36010280 http://dx.doi.org/10.3390/diagnostics12081930 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Yoon, Sumi
Hur, Mina
Kim, Hanah
Moon, Hee-Won
Yun, Yeo-Min
Reference Interval for the Axis-Shield Clinical Chemistry Heparin-Binding Protein Assay
title Reference Interval for the Axis-Shield Clinical Chemistry Heparin-Binding Protein Assay
title_full Reference Interval for the Axis-Shield Clinical Chemistry Heparin-Binding Protein Assay
title_fullStr Reference Interval for the Axis-Shield Clinical Chemistry Heparin-Binding Protein Assay
title_full_unstemmed Reference Interval for the Axis-Shield Clinical Chemistry Heparin-Binding Protein Assay
title_short Reference Interval for the Axis-Shield Clinical Chemistry Heparin-Binding Protein Assay
title_sort reference interval for the axis-shield clinical chemistry heparin-binding protein assay
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9406967/
https://www.ncbi.nlm.nih.gov/pubmed/36010280
http://dx.doi.org/10.3390/diagnostics12081930
work_keys_str_mv AT yoonsumi referenceintervalfortheaxisshieldclinicalchemistryheparinbindingproteinassay
AT hurmina referenceintervalfortheaxisshieldclinicalchemistryheparinbindingproteinassay
AT kimhanah referenceintervalfortheaxisshieldclinicalchemistryheparinbindingproteinassay
AT moonheewon referenceintervalfortheaxisshieldclinicalchemistryheparinbindingproteinassay
AT yunyeomin referenceintervalfortheaxisshieldclinicalchemistryheparinbindingproteinassay